Immunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 4,105 Shares of Stock

Immunovant, Inc. (NASDAQ:IMVTGet Free Report) CFO Eva Renee Barnett sold 4,105 shares of Immunovant stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $24.10, for a total value of $98,930.50. Following the completion of the transaction, the chief financial officer now directly owns 327,064 shares of the company’s stock, valued at $7,882,242.40. This represents a 1.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eva Renee Barnett also recently made the following trade(s):

  • On Wednesday, November 20th, Eva Renee Barnett sold 4,174 shares of Immunovant stock. The shares were sold at an average price of $25.45, for a total transaction of $106,228.30.
  • On Wednesday, November 20th, Eva Renee Barnett sold 4,174 shares of Immunovant stock. The stock was sold at an average price of $25.45, for a total transaction of $106,228.30.
  • On Wednesday, October 16th, Eva Renee Barnett sold 3,271 shares of Immunovant stock. The shares were sold at an average price of $28.79, for a total transaction of $94,172.09.

Immunovant Stock Performance

Shares of NASDAQ IMVT opened at $23.48 on Friday. The firm has a 50 day moving average price of $27.07 and a 200 day moving average price of $28.58. The stock has a market cap of $3.45 billion, a P/E ratio of -10.58 and a beta of 0.66. Immunovant, Inc. has a 52-week low of $23.08 and a 52-week high of $43.92.

Immunovant (NASDAQ:IMVTGet Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). During the same quarter in the prior year, the business earned ($0.45) EPS. Analysts predict that Immunovant, Inc. will post -2.73 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Raymond James reiterated an “outperform” rating and issued a $36.00 price objective on shares of Immunovant in a research report on Thursday, October 10th. Wolfe Research cut Immunovant from an “outperform” rating to a “peer perform” rating in a report on Friday, January 3rd. Oppenheimer boosted their price objective on Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, October 9th. HC Wainwright reaffirmed a “buy” rating and issued a $51.00 target price on shares of Immunovant in a research note on Friday, November 8th. Finally, Wells Fargo & Company dropped their price target on shares of Immunovant from $47.00 to $45.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $47.22.

Get Our Latest Stock Report on Immunovant

Institutional Investors Weigh In On Immunovant

Several large investors have recently modified their holdings of the business. Victory Capital Management Inc. grew its position in shares of Immunovant by 7.4% in the 3rd quarter. Victory Capital Management Inc. now owns 335,360 shares of the company’s stock valued at $9,561,000 after purchasing an additional 22,990 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Immunovant by 19.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 552,430 shares of the company’s stock worth $15,750,000 after acquiring an additional 91,259 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Immunovant by 69.9% during the third quarter. Principal Financial Group Inc. now owns 951,124 shares of the company’s stock worth $27,117,000 after acquiring an additional 391,436 shares during the period. Rubric Capital Management LP bought a new stake in Immunovant in the 2nd quarter valued at $1,548,000. Finally, First Turn Management LLC boosted its stake in Immunovant by 35.6% in the 2nd quarter. First Turn Management LLC now owns 695,428 shares of the company’s stock worth $18,359,000 after purchasing an additional 182,535 shares during the period. 47.08% of the stock is currently owned by institutional investors.

About Immunovant

(Get Free Report)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.

Featured Articles

Insider Buying and Selling by Quarter for Immunovant (NASDAQ:IMVT)

Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.